Pfizer offers medicines and vaccines in various therapeutic areas, including the following:
- Cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands
- Biologics, small molecules, immunotherapies and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena and Braftovi brands
- Sterile injectable and anti-infective medicines and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga and Paxlovid brands.
- Pneumococcal disease, meningococcal disease, tick-borne encephalitis and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba and the Prevnar family brands
- Biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo brands
- Amyloidosis, hemophilia and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX and Genotropin brands
Pfizer stock comes with a 4.43% dividend. Cantor Fitzgerald’s $75 price objective is well above the consensus target of $44.34 and Tuesday’s $36.84 closing share price.
Verizon Communications
This top telecommunications stock offers tremendous value at current levels. Verizon Communications Inc. (NYSE: VZ) is one of the largest U.S. telecom companies. It provides wireless and wireline service to retail, enterprise and wholesale customers.
Verizon’s wireless network serves approximately 120 million mobile connections with 115 million postpaid subscribers. Verizon’s wireline business has undergone a period of secular decline due to wireless substitution and cable competition.
The company also provides converged communications, information and entertainment services over America’s most advanced fiber-optic network, and it delivers integrated business solutions to customers worldwide.
Verizon has been hit hard over concerns over lead landline issues, but the company posted solid second-quarter results as it reported an unexpected increase in wireless subscriber numbers.
Shareholders receive a 7.87% dividend. Verizon Communications stock has a $49 price objective at Cowen. The consensus target is $43.67, and shares closed at $33.20 on Tuesday.
The artificial intelligence tech rally has reminded many of the dot-com rally and implosion in the late 1990s and early 2000s. While the valuations may not be quite as stretched, the frothing mania certainly is similar. For young investors with a long timeline and big risk tolerance, as long as they stay off margin, they all should be fine. However, for those looking to take the money and run, now is a good time, and these picks are ideal for what could be a rough autumn.
Originally published at 24/7 Wall St.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
